Fig. 5: In vivo evaluation of ICG@CCM-AuNC-PO2-Hb with nanovesicle secretion.

a In vivo distribution of free ICG, ICG-AuNC-PO₂-Hb and ICG@CCM-AuNC-PO₂-Hb in tumor-bearing mice at different time points. Scale bars =2 cm. b Ex vivo imaging of the collected organs and tumors from the mice after injection for 24 h. Scale bars =1 cm. c Therapeutic regimen of 4T1 tumor-bearing mice with ICG@CCM-AuNC-PO₂-Hb. d Collected tumors (left) and representative images of mice (right) from group (6). Embedded boxes (right) are images representing their (small boxes on left) enlargements, respectively. e Tumor volumes of 4T1 tumor-bearing mice during the treatments. f Tumor weights of the mice after administrating our bubble nanomachines. g H&E staining of the collected tumors (scale bars = 50 μm). h–j Alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (UREA), creatinine (CRE), total cholesterol (TC) and triglyceride (TG) of 4T1 tumor-bearing mice after treatments. (1) PBS; (2) ICG@CCM-AuNC + NIR; (3) AuNC-PO₂-Hb + NIR; (4) CCM-AuNC-PO₂-Hb + NIR; (5) ICG@CCM-AuNC-PO₂-Hb; (6) ICG@CCM-AuNC-PO₂-Hb + NIR. For 5 e, f, n  =  5 biologically independent animals. For 5 h–j, n  =  3 biologically independent samples. Data are presented as means ± SD. Significant differences were evaluated by two-tailed unpaired t-test. Experiments were performed three times (g), with similar results. Source data are provided as a Source Data file.